Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings results on Tuesday. The company reported $2.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.06, Bloomberg Earnings reports. Johnson & Johnson had a return on equity of 30.05% and a net margin of 1.58%. The company had revenue of $20.01 billion during the quarter, compared to the consensus estimate of $19.50 billion. During the same period last year, the business earned $1.83 EPS. The business’s quarterly revenue was up 12.6% on a year-over-year basis. Johnson & Johnson updated its FY18 guidance to $8.00-8.20 EPS.
JNJ opened at $127.72 on Thursday. The company has a market capitalization of $350,226.03, a price-to-earnings ratio of 17.50, a price-to-earnings-growth ratio of 2.08 and a beta of 0.74. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a 12-month low of $121.11 and a 12-month high of $148.32.
A number of equities research analysts have recently weighed in on the company. Vetr downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $124.55 price target for the company. in a research note on Thursday, April 5th. JPMorgan Chase downgraded Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $145.00 price target for the company in a research note on Wednesday, April 11th. Deutsche Bank reissued a “buy” rating on shares of Johnson & Johnson in a report on Wednesday. Finally, Jefferies Group set a $165.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a report on Monday, February 26th. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average target price of $142.98.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the sale, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.22% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Landmark Financial Advisors LLC grew its holdings in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock worth $259,000 after purchasing an additional 7 shares in the last quarter. Premier Asset Management LLC grew its holdings in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after purchasing an additional 12 shares in the last quarter. Lbmc Investment Advisors LLC grew its holdings in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock worth $492,000 after purchasing an additional 14 shares in the last quarter. Halbert Hargrove Russell LLC grew its holdings in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock worth $466,000 after purchasing an additional 15 shares in the last quarter. Finally, Lenox Wealth Management Inc. grew its holdings in shares of Johnson & Johnson by 1.7% during the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after purchasing an additional 24 shares in the last quarter. 67.23% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This article was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2018/04/19/johnson-johnson-jnj-posts-earnings-results-beats-expectations-by-0-06-eps.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.